Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 15 2022 - 4:20PM
Business Wire
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a
biopharmaceutical company focused on discovering, developing, and
commercializing important new medicines to improve the lives of
people with cancer, today announced that in connection with the
hiring of Kelley Dealhoy, Senior Vice President and Chief Business
Officer, the Compensation Committee of Deciphera’s Board of
Directors approved the grant of a stock option to purchase 100,000
shares of Deciphera’s common stock and 45,000 restricted stock
units (“RSUs”) to Ms. Dealhoy with a grant date of July 15,
2022.
The equity awards were granted under the Company’s 2022
Inducement Plan and were made pursuant to Nasdaq Listing Rule
5635(c)(4). The grants were an inducement material to Ms. Dealhoy
accepting employment with the Company. The options have a ten-year
term, and the exercise price of the options is $13.01, equal to the
fair market value of the Company’s common stock on the Nasdaq on
July 15, 2022. The shares subject to the option vest over a
four-year period, with 25 percent of the shares subject to the
option vesting on the first anniversary of Ms. Dealhoy’s date of
hire and the remainder vesting in equal monthly installments over
three years thereafter. One-third of the shares underlying 25,000
of the RSUs will vest annually over a three-year period beginning
on or about the one-year anniversary of the grant date. A grant of
20,000 RSUs will vest in full on or about the one-year anniversary
of the grant date. The awards are subject to the terms and
conditions of their applicable equity award agreements, including
having a continued relationship with the Company on the vesting
date.
About Deciphera Pharmaceuticals
Deciphera is a biopharmaceutical company focused on discovering,
developing, and commercializing important new medicines to improve
the lives of people with cancer. We are leveraging our proprietary
switch-control kinase inhibitor platform and deep expertise in
kinase biology to develop a broad portfolio of innovative
medicines. In addition to advancing multiple product candidates
from our platform in clinical studies, QINLOCK® is Deciphera’s
switch control inhibitor for the treatment of fourth-line GIST.
QINLOCK® is approved in Australia, Canada, China, the European
Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the
United States. For more information, visit www.deciphera.com and
follow us on LinkedIn and Twitter (@Deciphera).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220715005381/en/
Investor Relations: Maghan Meyers Argot Partners
Deciphera@argotpartners.com 212-600-1902
Media: David Rosen Argot Partners
david.rosen@argotpartners.com 212-600-1902
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Jul 2023 to Jul 2024